#United States #New York #Pomerantz LLP #Septerna Inc #SEPN

Pomerantz Law Firm Investigates Septerna, Inc.

Pomerantz LLP has commenced an investigation into potential claims from investors of Septerna, Inc. (NASDAQ: SEPN). This inquiry comes in light of serious allegations surrounding the company and its operational practices. Investors are encouraged to reach out to Pomerantz for further guidance on the matter.

Background on the Investigation

On October 25, 2024, Septerna made headlines by launching its initial public offering (IPO), issuing 18.4 million shares at a price of $18.00 each. Excitement surrounded the company, aiming to build momentum in the biotechnology sector. However, that optimism faced a significant challenge on February 18, 2025, when Septerna publicly announced a critical decision: it would discontinue its Phase 1 clinical trial for SEP-786, a drug that was under development.

This discontinuation stemmed from the discovery of two unanticipated severe Grade 3 events associated with elevated bilirubin levels observed during the clinical trials, despite the absence of liver enzyme elevation. As a direct result of this news, the company's stock plummeted by $6.09, marking a staggering 46.99% drop that left many investors reeling.

What This Means for Investors

The investigation led by Pomerantz LLP seeks to determine whether Septerna and its executives may have engaged in wrongful practices or securities fraud. Investors who feel they have been misled or harmed by the company’s actions are urged to participate in this class action investigation. Pomerantz has a long-standing reputation for advocating for investors, particularly in cases of securities fraud, and they are eager to help those affected by this situation.

Pomerantz's Commitment

Pomerantz LLP has built a prestigious portfolio, being one of the leading firms specializing in corporate, securities, and antitrust litigation. Founded by Abraham L. Pomerantz, often hailed as the father of the class action, the firm has championed the rights of investors for over 85 years. They are particularly noted for securing significant damages in cases involving corporate wrongdoing. Their involvement in the Septerna investigation reaffirms their commitment to safeguarding investor interests.

For those interested in joining the investigation or seeking advice on how to proceed, Pomerantz encourages individuals to contact Danielle Peyton directly via email at dpayton@pomlaw.com, or by phone at 646-581-9980, extension 7980.

Conclusion

Events like the one surrounding Septerna remind investors of the inherent risks in the biotech sector and the importance of vigilant participation in market activities. As Pomerantz Law Firm delves into this investigation, impacted investors can seek justice and understand their rights. The firm's expertise could play a crucial role in determining the next steps for those affected by this alarming turn of events in Septerna's journey.